Anzeige
Mehr »
Samstag, 30.08.2025 - Börsentäglich über 12.000 News
Megatrend Uran: Die Nachfrage nach Uran explodiert - greift jetzt Buffetts Erfolgsrezept?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7EK | ISIN: JP3431300007 | Ticker-Symbol: JSS
Frankfurt
29.08.25 | 08:03
5,300 Euro
+1,92 % +0,100
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
NXERA PHARMA CO LTD Chart 1 Jahr
5-Tage-Chart
NXERA PHARMA CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
5,2005,55029.08.

Aktuelle News zur NXERA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.08.Nxera Pharma reports Q2 results1
08.08.Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025131Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
► Artikel lesen
NXERA PHARMA Aktie jetzt für 0€ handeln
06.08.Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share18
06.08.Nxera Pharma: Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management137Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscapeDesigned...
► Artikel lesen
29.07.Singtel's Data Centre Arm Nxera Embarks on Ambitious Hiring Plan for AI Skills1
04.07.Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study2
04.07.Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist202Tokyo, Japan and Cambridge, UK, 4 July 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals...
► Artikel lesen
03.06.Nxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly9
03.06.Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568165Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first...
► Artikel lesen
02.06.Nxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research537INDIANAPOLIS (dpa-AFX) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY)...
► Artikel lesen
02.06.Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases224Tokyo, Japan and Cambridge, UK, 2 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration...
► Artikel lesen
02.05.Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025191Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter...
► Artikel lesen
01.05.Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia225NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information...
► Artikel lesen
01.05.Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations1
03.04.Nxera Pharma appoints AstraZeneca alum as inaugural commercial chief3
01.04.Nxera Pharma Announces Appointments to its Executive Leadership Team1
25.03.Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder313Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a...
► Artikel lesen
14.02.Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024413Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for...
► Artikel lesen
05.12.24Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea222Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is expected...
► Artikel lesen
13.11.24Nxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist361Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 - Nxera Pharma Co., Ltd. ("Nxera"...
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1